title: How many grails do we need?
authors.affiliation: Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, Minn 55905, USA. holmes.david@mayo.edu
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes
mesh_terms: D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000628:therapy; D004343:Drug Implants; D000068338:Everolimus; D005500:Follow-Up Studies; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D016037:Single-Blind Method; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015607:Stents; D016896:Treatment Outcome
chemical_list: D004343:Drug Implants; D006131:Growth Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus